Valuation: CSL Limited

Market Cap 57.4B 49.45B 46.82B 42.44B 79.62B 5,483B 80.03B 556B 214B 2,790B 216B 211B 8,815B P/E 2027 *
19.6x
P/E 2028 * 17.8x
Enterprise Value 66.33B 57.15B 54.11B 49.05B 92.01B 6,336B 92.48B 643B 247B 3,224B 249B 244B 10,187B EV / Sales 2027 *
4.21x
EV / Sales 2028 * 4.04x
Free-Float
99.97%
Yield 2027 *
2.5%
Yield 2028 * 2.65%
1 day+2.68%
1 week-0.93%
1 month+25.69%
3 months+62.58%
6 months+21.97%
Current year-0.63%
1 week 165.79
Extreme 165.79
174.8
1 month 134.6
Extreme 134.6
177.39
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.68%-0.93%-16.09%-35.72% 57.4B
-1.48%-5.59%+39.55%-5.42% 78.04B
+5.38%-1.09%+512.38%+32.58% 57.48B
-0.56%-2.21%-11.34%+27.29% 48.81B
+1.51%-0.76%+1.56%+153.15% 45.5B
+0.80%-1.67%+49.90%-15.15% 32.08B
-1.47%-4.17%+46.17%+92.50% 24.62B
+3.53%-4.39%+1.31%+156.56% 20.77B
+1.96%-0.98%+63.22%+98.93% 15.75B
-0.08%-3.21%+41.46%+155.97% 14.16B
Average +0.83%-3.81%+72.81%+66.07% 39.46B
Weighted average by Cap. +0.65%-3.69%+89.91%+41.84%

Financials

2027 *2028 *
Net sales 15.76B 13.58B 12.86B 11.66B 21.87B 1,506B 21.98B 153B 58.73B 766B 59.2B 57.9B 2,421B 16.31B 14.05B 13.31B 12.06B 22.63B 1,558B 22.74B 158B 60.78B 793B 61.26B 59.91B 2,505B
Net income 2.84B 2.44B 2.31B 2.1B 3.94B 271B 3.96B 27.49B 10.57B 138B 10.66B 10.42B 436B 3.17B 2.73B 2.58B 2.34B 4.39B 302B 4.41B 30.68B 11.8B 154B 11.89B 11.63B 486B
Net Debt 8.93B 7.69B 7.29B 6.6B 12.39B 853B 12.45B 86.53B 33.28B 434B 33.54B 32.8B 1,372B 8.46B 7.29B 6.9B 6.26B 11.74B 808B 11.8B 82B 31.53B 411B 31.78B 31.08B 1,300B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-14 A$171.57 +2.68% 1,078,021
26-09-11 A$167.10 -1.42% 806,570
26-09-10 A$169.50 -1.00% 1,090,729
26-09-09 A$171.21 -2.05% 1,248,921
26-09-08 A$174.80 +0.94% 954,984
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
119.85USD
Average target price
123.23USD
Spread / Average Target
+2.83%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!